Marken Announces Depot in Russia; Makes Senior Appointment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Marken Announces Depot in Russia; Makes Senior Appointment



Marken, a provider of clinical-trial material supply solutions, has added a depot in Moscow as part of its global pharmaceutical depot network. The Russian depot will be located within an existing GxP-compliant storage facility in Moscow. The facility will be operated by staff trained on Marken’s global procedures and managed by the inventory system, Solo. It joins Marken’s current network of depots in China, Singapore, Argentina, Mexico, Germany, and the United States.

Marken’s network of pharmaceutical depot facilities and supporting IT systems are designed to provide storage and distribution of materials for clinical trials. They are designed for all clinical materials, including temperature-controlled and time-sensitive products.

In other news, Marken has appointed Michael Culme-Seymour as vice-president, Asia Pacific Region, effective Oct. 14, 2013. Culme-Seymour will be responsible for clinical logistics and Marken’s seven branches in the region, including: Singapore, Australia, India, China, Japan, Hong Kong, and Korea. Culme-Seymour has 22 years of logistics experience with airlines, express couriers, and major post companies in Singapore, Zurich, and London.  He was most recently owner of Fischer Road Express, a private company specializing in life-science logistics. 

Source: Marken

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here